CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.

Authors :: Walls GM
Oughton JB
Chalmers AJ
Brown S
Collinson F
Forster MD
Franks KN
Gilbert A
Hanna GG
Hannaway N
Harrow S
Haswell T
Hiley CT
Hinsley S
Krebs M
Murden G
Phillip R
Ryan AJ
Salem A
Sebag-Montefoire D
Shaw P
Twelves CJ
Walker K
Young RJ
Faivre-Finn C
Greystoke A
Source :: Clinical and translational radiation oncology [Clin Transl Radiat Oncol] 2020 Sep 22; Vol. 25, pp. 61-66. Date of Electronic Publication: 2020 Sep 22 (Print Publication: 2020).
Publication Year :: 2020
Abstract: Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.<br />Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (© 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.)

Full Text Access

Tools